German pharmaceutical packaging manufacturer Gerresheimer AG saw its stock price plummet on February 11, 2026, after announcing a delay in its 2025 financial results and the initiation of a sale of its U.S.-based Centor Inc. Subsidiary. The company’s shares fell by over 30% in morning trading, signaling significant investor concern.
The delay stems from an ongoing review of the company’s accounting practices by Germany’s financial regulator, BaFin, and an additional auditing firm. According to the company, potential errors have been identified in the presentation of revenue and earnings for both 2024, and 2025. This news comes as Gerresheimer, a leading provider of specialty packaging and system solutions for the pharmaceutical and healthcare industries, faces increased scrutiny.
Gerresheimer also warned that its 2025 results are likely to be considerably worse than previously expected, anticipating a sharper revenue decline, lower margins, and potentially a negative adjusted result. The planned sale of Centor Inc. Is intended to improve the company’s capital and financial structure.
The announcement triggered a wave of negative reactions from investors, with discussions on wallstreetONLINE’s community forum quickly escalating. One user, “Exelrde,” commented, “It’s a heart attack right before falling asleep, frankly amazing. However, I don’t think the news is that bad. The blame is being shifted to former employees, and the numbers would have been bad anyway. The highlight is the sale of Centor. There’s definitely something to be made there…”
Other forum participants expressed more severe criticism. “blackstarrider” stated, “Only the public prosecutor’s office can help now! What a mess.” “Einkaeufer” added, “No wonder assets are being sold now. Hopefully, they’ll hold the former CEO/CFO accountable 😡.”
Several users questioned potential market manipulation, with “Wolfin” asking, “Why not sue Gerresheimer for market manipulation now? Why not? Probably a high success rate.”
+3,52 %
-22,85 %
-30,49 %
-21,54 %
-75,74 %
-70,09 %
-79,75 %
-73,05 %
-54,55 %
ISIN:DE000A0LD6E6WKN:A0LD6E
Despite the negative sentiment, some investors attempted to uncover a silver lining. “Bud_Fo_x” offered a more optimistic outlook, stating that the sale of Centor could generate over €1 billion, allowing the company to reduce its debt. They also pointed to plans to close a manufacturing facility in Chicago Heights, USA, by the end of 2026, and streamline the “Moulded Glass” division for potential sale.
“Investment-Logik” echoed this sentiment, suggesting that the sale of assets, while painful, could position Gerresheimer as a high-profitability medtech company focused on areas like GLP-1 pens and syringes.
However, other forum users remained highly skeptical. “smallvalueinvestor” expressed outrage, stating, “What a dump! They cheated me. Where is BaFin? Shut it down and compensate the investors. I’ll never touch this again! I’ve had enough.”
“Professordeluxe” acknowledged the severity of the situation, stating, “Blow after blow, kick after kick… As a Gerresheimer shareholder, you have to be very resilient. But I remain on board and will continue to increase my position. But everyone has to decide that for themselves.”
“Aktienfreundlongonly” called for accountability, stating, “It’s not just individual employees responsible; the entire board bears responsibility and must face the consequences.” “Dogweiler” went further, suggesting potential accounting fraud, drawing comparisons to the Wirecard scandal.
“Dlg” summarized the situation, noting the company’s transparency regarding the issues and the potential for a significant impact on the stock price.
“Stockfreek” concluded with a long-term perspective, advising investors to revisit the stock in five to six years.
As of February 13, 2026, Gerresheimer AG’s stock closed at €19.89, a 4.52% increase on the day, but still reflecting substantial year-to-date losses. The company’s earnings date is scheduled for February 26, 2026.
Founded in 1864 and employing 13,535 people, Gerresheimer AG provides medicine packaging, drug delivery devices, and solutions internationally, operating through Plastics & Devices, Primary Packaging Glass, and Advanced Technologies divisions.
